Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Journal of Immunotherapy

Volumn 39, Issue 9, 2016, Pages 379-382

  Diem, Stefan ^a,b   Keller, Fabienne ^a   Rüesch, Reinhard ^a   Maillard, Samia A ^c   Speiser, Daniel E ^c   Dummer, Reinhard ^d   Siano, Marco ^a   Urner Bloch, Ursula ^e   Goldinger, Simone M ^d   Flatz, Lukas ^a,d  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Breast Center   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

immunotherapy; melanoma; uveitis

Indexed keywords

ANTIBIOTIC AGENT; B RAF KINASE; DORZOLAMIDE PLUS TIMOLOL; IPILIMUMAB; MYDRIATIC AGENT; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PEMBROLIZUMAB; PREDNISOLONE ACETATE; SCOPOLAMINE; STEROID; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CATARACT EXTRACTION; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOPHTHALMITIS; HUMAN; HUMAN TISSUE; INTRAOCULAR PRESSURE ABNORMALITY; LIVER METASTASIS; LYMPH NODE METASTASIS; MACULAR EDEMA; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OPTICAL COHERENCE TOMOGRAPHY; PEMBROLIZUMAB INDUCED UVEITIS; PRIORITY JOURNAL; RASH; RETINA MACULA CYSTOID EDEMA; SKIN BIOPSY; TUMOR REGRESSION; UVEITIS; VISUAL DISORDER; WILD TYPE METASTATIC MELANOMA; AUTOIMMUNITY; CANCER OF UNKNOWN PRIMARY SITE; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; PROCEDURES; SECONDARY; SKIN TUMOR; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNITY; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TREATMENT OUTCOME; UVEITIS;

EID: 84988672464     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000143     Document Type: Article

References (12)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372:2521-2532.
4. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-918.
5. Robert C, Ribas A, Wolchok JD, et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384: 1109-1117.
6. Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51:e4-e6.
7. Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2015;26:e46-e48.
8. Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009;116:981.e1-989.e1.
9. Palmer DC, Chan C-C, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105:8061-8066.
10. de Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452-470.
11. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal antiinflammatory drugs in ophthalmology. Surv Ophthalmol. 2010; 55:108-133.
12. Foster CS, Kothari S, Anesi SD, et al. The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61:1-17.